A Phase I, open-label, dose-finding study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers (NCT04958239)
AUC, area under the curve; Cmax, peak serum concentration; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, informed consent; ICH-GCP, International Conference on Harmonisation version of good clinical practice; MTD, maximum tolerated dose; RECIST, Response Evaluation Criteria in Solid Tumors; ss, steady-state.